Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Alterity Therapeutics ( (AU:ATH) ).
Alterity Therapeutics Limited has announced the quotation of 1,283,942 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of August 22, 2025. This move reflects the company’s ongoing efforts to strengthen its financial position and enhance its market presence, potentially impacting its operational capabilities and offering new opportunities for investors.
More about Alterity Therapeutics
Alterity Therapeutics Limited operates in the biotechnology industry, focusing on developing therapies for neurodegenerative diseases. The company is primarily engaged in creating treatments that target disorders such as Alzheimer’s and Parkinson’s, aiming to address significant unmet medical needs in these areas.
YTD Price Performance: 30.0%
Average Trading Volume: 13,630,854
Technical Sentiment Signal: Sell
Current Market Cap: A$119.7M
For a thorough assessment of ATH stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
- “…Lack of Confidence in the Israeli Management”: Microsoft Stock (NASDAQ:MSFT) Slips as Israeli Connections Examined
- “We Think Investors Can Buy Optimus For Free”: Piper Sandler Assessment Sends Tesla Stock (NASDAQ:TSLA) Blasting Up
- Hitting the $4 Wall: Starbucks Stock (NASDAQ:SBUX) Notches Up Despite New Value Competitor